Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4543-4553

  Wu, Jianzhang ^a   Ji, Jiansong ^b   Weng, Bixia ^a   Qiu, Peihong ^a   Kanchana, Karvannan ^a   Wei, Tao ^a   Wang, Yi ^a   Cai, Yuepiao ^a   Li, Xiaokun ^a   Liang, Guang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b LISHUI CENTRAL HOSPITAL   (China)

Author keywords

Anti cancer activity; Fibroblast growth factor receptor 1; NDGA; Non ATP competitive FGFR1 inhibitors; Non small cell lung cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; AEA 25; AEA 4; CYCLIN D1; CYCLOOXYGENASE 2; ENZYME INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; TUMOR XENOGRAFT; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IN VITRO TECHNIQUES; LUNG NEOPLASMS;

EID: 84905123779     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2122     Document Type: Article

References (37)

1. Gerber DE, Schiller JH. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31: 1009-1020.
2. Gan HK, Burgess AW, Clayton AH, Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer research. 2012; 72: 2924-2930.
3. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8: 235-253.
4. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer research. 2012; 72: 1909-1914.
5. Xu AM, Huang PH. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res. 2010; 70: 3857-3860.
6. Fischer B, Marinov M, Arcaro A. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev. 2007; 33: 391-406.
7. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10: 116-129.
8. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science translational medicine. 2010; 2: 62ra93.
9. Malchers F, Dietlein F, Schottle J, Lu X, Nogova L, Albus K, Fernandez-Cuesta L, Heuckmann JM, Gautschi O, Diebold J, Plenker D, Gardizi M, Scheffler M et al. Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer. Cancer discovery. 2014; 4: 246-257.
10. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012; 18: 1855-1862.
11. Ho HK, Yeo AH, Kang TS, Chua BT. Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. Drug discovery today. 2014; 19: 51-62.
12. Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y, Liu K, Dong Z, Zhu G, Qian Z et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res. 2012; 18: 6658-6667.
13. Liang G, Liu Z, Wu J, Cai Y, Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci. 2012; 33: 531-541.
14. Eathiraj S, Palma R, Hirschi M, Volckova E, Nakuci E, Castro J, Chen CR, Chan TC, France DS, Ashwell MA. A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor. J Biol Chem. 2011; 286: 20677-20687.
15. Liang G, Chen G, Wei X, Zhao Y, Li X. Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine & growth factor reviews. 2013; 24: 467-475.
16. Garuti L, Roberti M, Bottegoni G. Non-ATP competitive protein kinase inhibitors. Current medicinal chemistry. 2010; 17: 2804-2821.
17. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009; 9: 28-39.
18. Meyer AN, McAndrew CW, Donoghue DJ. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells. Cancer Res. 2008; 68: 7362-7370.
19. Krejci P, Murakami S, Prochazkova J, Trantirek L, Chlebova K, Ouyang Z, Aklian A, Smutny J, Bryja V, Kozubik A, Wilcox WR. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. J Biol Chem. 2010; 285: 20644-20653.
20. Wang Y, Cai Y, Ji J, Liu Z, Zhao C, Zhao Y, Wei T, Shen X, Zhang X, Li X, Liang G. Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer. Cancer Lett. 2014; 344: 82-89.
21. Lu JM, Nurko J, Weakley SM, Jiang J, Kougias P, Lin PH, Yao Q, Chen C. Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update. Medical science monitor: international medical journal of experimental and clinical research. 2010; 16: RA93-100.
22. Blecha JE, Anderson MO, Chow JM, Guevarra CC, Pender C, Penaranda C, Zavodovskaya M, Youngren JF, Berkman CE. Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs. Bioorganic & medicinal chemistry letters. 2007; 17: 4026-4029.
23. Meyer GE, Chesler L, Liu D, Gable K, Maddux BA, Goldenberg DD, Youngren JF, Goldfine ID, Weiss WA, Matthay KK, Rosenthal SM. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. Journal of cellular biochemistry. 2007; 102: 1529-1541.
24. Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast cancer research and treatment. 2005; 94: 37-46.
25. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle. 2009; 8: 580-588.
26. Schultheis AM, Bos M, Schmitz K, Wilsberg L, Binot E, Wolf J, Buttner R, Schildhaus HU. Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2014; 27: 214-221.
27. Tran TN, Selinger CI, Kohonen-Corish MR, McCaughan BC, Kennedy CW, O'Toole SA, Cooper WA. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer. 2013; 81: 462-467.
28. Yang J, Zhao H, Xin Y, Fan L. MicroRNA-198 Inhibits Proliferation and Induces Apoptosis of Lung Cancer Cells Via Targeting FGFR1. Journal of cellular biochemistry. 2014; 115: 987-995.
29. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer discovery. 2013; 3: 264-279.
30. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des. 2007; 13: 2025-2044.
31. Kirkland LO, McInnes C. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochemical pharmacology. 2009; 77: 1561-1571.
32. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, Gray NS, Meyerson M. Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer. PLoS One. 2011; 6: e20351.
33. Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA, Iafrate AJ. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 2012; 7: 1775-1780.
34. Ren M, Hong M, Liu G, Wang H, Patel V, Biddinger P, Silva J, Cowell J, Hao Z. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep. 2013; 29: 2181-2190.
35. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012; 72: 2045-2056.
36. Luo JC, Lin HY, Lu CL, Wang LY, Chang FY, Lin HC, Huang YC, Ng KM, Chi CW, Lee SD. Dexamethasone inhibits basic fibroblast growth factor-stimulated gastric epithelial cell proliferation. Biochemical pharmacology. 2008; 76: 841-849.
37. Pai R, Dunlap D, Qing J, Mohtashemi I, Hotzel K, French DM. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res. 2008; 68: 5086-5095.